Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue: 2019-2021

Historic Non-Current Deffered Revenue for Fulcrum Therapeutics (FULC) over the last 3 years, with Dec 2021 value amounting to $1.7 million.

  • Fulcrum Therapeutics' Non-Current Deffered Revenue fell 43.45% to $1.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.7 million, marking a year-over-year decrease of 43.45%. This contributed to the annual value of $1.7 million for FY2021, which is 43.45% down from last year.
  • Fulcrum Therapeutics' Non-Current Deffered Revenue amounted to $1.7 million in FY2021, which was down 43.45% from $3.0 million recorded in FY2020.
  • In the past 5 years, Fulcrum Therapeutics' Non-Current Deffered Revenue registered a high of $6.0 million during FY2019, and its lowest value of $1.7 million during FY2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $3.0 million (2020), whereas its average is $3.6 million.
  • Data for Fulcrum Therapeutics' Non-Current Deffered Revenue shows a maximum YoY slumped of 50.57% (in 2020) over the last 5 years.
  • Fulcrum Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $6.0 million in 2019, then tumbled by 50.57% to $3.0 million in 2020, then tumbled by 43.45% to $1.7 million in 2021.